Naltrexone - a proven and effective treatment for ms - also covers a multitude of ailments and conditions. Easing symptoms, from Crohns disease and types of cancer, to HIV/AIDS and rheumatoid arthritis, Naltrexone is more than just a multiple sclerosis treatment. It works across numerous immune related disorders.
The results of Low Dose Naltrexone - known as LDN therapy - have been remarkable. Originally Naltrexone’s primary use was in the management of opioid and alcohol dependence, which utilise high doses. Lower dose amounts have seen reported benefits as a multiple sclerosis treatment, Crohns disease treatment and across many immunological related diseases, especially in the treatment of MS, where patients have reported improved quality of life. A leading study further concluded that by maintaining regular nightly LDN therapy, less than 1% of the MS sufferer’s experienced fresh MS attacks.
Running contrary to the common theory that many immune related ailments are caused by an overactive immune system - LDN therapy works on the basis that autoimmune diseases develop as a result of immunodeficiency – a lack of immune system activity. More specifically, LDN therapy works on the theory that low blood levels of endorphins contribute to disease-associated immune deficiencies.
Since the mid-eighties, Naltorexone has been used in the treatment of drug and alcohol addiction. Here, a 50mg daily dose of Naltrexone acts to block the endorphin/opioid receptors for a full 24 hours. This stops the addict from gaining any pleasure from the drugs/alcohol that they have taken or consumed. Dr Bhari pioneered clinical trials in the treatment of the previously thought untreatable HIV/AIDS, with LDN. He cites that with a Low dosage of Naltorexone ( LDN therapy ), the receptor block is only temporary – lasting but a few hours. During this time, the endorphins cannot attach to the receptors and the body compensates by creating more endorphins. The net result of this is that healthy levels of endorphins are established in the body.
In effect LDN boosts the immune system and so helps those suffering from disorders where the immune system plays a central role. This is the reason why LDN does not just help those with autoimmune diseases but also illnesses like HIV/Aids and certain cancers.
LDN therapy has been shown to increase the body's production of met-enkephalin and beta endorphins, and can also double or even triple the activity of natural killer cells ( NK cells ). NK cells form a distinct group of lymphocytes - the white blood cells that are integral to the body’s immune system - and form 5 to 16% of the total lymphocyte population. Their specific function is to kill infected and cancerous cells, so by increasing the number of NK cells, diseased cells can be addressed more efficiently.
Recent studies of MS sufferers have shown that they have abnormally low levels of beta-endorphins. And since 2005 at least 3 separate scientific reports have described an underlying immunodeficiency as being a characteristic of four different autoimmune diseases - Crohn’s disease, rheumatoid arthritis, chronic fatigue syndrome and multiple sclerosis. LDN therapy has also been put forward as a treatment for: Fibromyalgia – a painful rheumatic condition, Cancers that have ovoid receptors – working to shrink tumours and inhibit their growth, HIV/AIDS, Lupus, Psoriasis and many others where the immune system is under attack.
Known as +narvcol as well as Naltrexone, a regular dose of 5mg Naltrexone should be taken before bedtime – ideally between 9pm and 3am for maximum efficiency. The side effects, if felt, are minimal and rare. Nausea and sleep interruption affect a proportion of users for the first few days, leading the drug to be classed as extremely well tolerated.
With many additional benefits to the immune system, Naltroxone is a widely recognised and effective drug suitable for a myriad of conditions.
Customers Who Bought This Item Also Bought
I am so pleased that you are now offering naltrexone in a low dose form- it’s a really important find for me.
C.P., California.